Equine pregnancy is characterized by very high circulating concentrations of estrogens. The physiological roles of estrogens during equine gestation are largely unknown, although some studies suggest a role in the regulation of uterine artery hemodynamics and a relationship between low circulating estrogen concentrations and late pregnancy loss. The objectives of this experiment were to evaluate the effects of estrogen suppression on uterine artery hemodynamics and on pregnancy outcome. Estrogen synthesis was suppressed using letrozole, a potent aromatase inhibitor. Twelve pregnant mares were randomly assigned to a control (n = 6) or treatment (n = 6; 500 mg letrozole orally every 4 days) group with treatment starting at 240 days of gestation and continuing until parturition. Weekly serum samples were analyzed to determine testosterone, dehydroepiandrosterone sulfate, estradiol, estrone sulfate, progestins, and prostaglandin F2α metabolite concentrations. Ultrasonographic examinations were performed biweekly and measurements included uterine artery hemodynamics (diameter, pulsatility, and resistance indices), fetal growth using the diameter of the fetal eye, and placental evaluation using the combined thickness of the uterus and placenta. At parturition, gestational length, foal weight, and neonatal viability were determined. Letrozole suppressed estrogen synthesis during gestation by approximately 90% compared to control values. This large reduction in circulating estrogens had no effect on uterine artery hemodynamics, normal placental development, maintenance of pregnancy, or neonatal viability. However, neonates from letrozole-treated mares had lower (P < 0.05) birth weights than controls, suggesting that estrogens may play a role in fetal growth that is not mediated through regulation of uterine blood flow. 
Introduction
Estrogens are produced throughout equine gestation, although the source of estrogens varies depending on the stage of pregnancy. During early pregnancy, estrogens are produced by the conceptus and are present in the yolk sac fluid [1, 2] . Estrone, estradiol, and their sulfoconjugates are present in increasing concentrations in the yolk sac fluid of equine conceptuses from day 10 to day 26 of gestation [1] . Estrogens are also produced by primary corpus luteum and accessory copora lutea from day 35 of gestation, and increases in peripheral concentrations are first detectable at this point [3, 4] . From approximately day 80 of pregnancy, there is a steep rise in circulating estrogens which peaks around 200 to 250 days and then slowly declines until parturition [5] . This pattern is different to those found in humans and in other domestic species in which estrogen levels continue to increase until term [6] [7] [8] [9] [10] . The fetoplacental unit, first described in women by Diczfalusy and Mancuso [11] and in mares by Raeside et al. [12] , appears to be the source of estrogens in pregnant mares beyond 80 days of gestation [13] [14] [15] [16] . The rise and fall in estrogens parallels the enlargement and regression of the fetal gonads, where androgens are produced as estrogen precursors before being aromatized in the placenta [15, 16] .
Although different sources of estrogen have been well characterized, little is known about their role during equine pregnancy. Early studies by Pashen and Allen concluded that estrogens were not necessary for the maintenance of pregnancy, lactogenesis, or initiation of labor, but that estrogens were essential for normal fetal development [17, 18] . The mechanism was suggested through regulation of uterine and placental blood flow. This idea is supported by studies in nonpregnant sheep where several estrogens, such as estrone, estradiol, or estriol, elicit a marked increase in uterine blood flow [7, [19] [20] [21] .
Peripheral concentrations of estrogens have been used as an indicator of fetoplacental compromise in the pregnant mare. Circulating estrone sulfate concentrations decreased sharply after the induction of abortion [22] , and peripheral estradiol concentrations decline in pregnant mares with placental dysfunction [23] . Because of this association, estrogens are monitored during pregnancy in mares suspected to be at risk of pregnancy loss. Although the decline in estradiol associated with placental dysfunction is thought to reflect placental disease per se, some clinical studies suggest estrogen supplementation as a means to prevent abortions associated with placental disease in mares [24, 25] . Ultimately, the importance of the high concentrations of estrogens during equine pregnancy is poorly defined.
The final step of estrogen synthesis is mediated by placental aromatase; this enzyme catalyzes the aromatization of androgens to estrogens [26] . This step can be blocked with letrozole a highly selective, third-generation, nonsteroidal, aromatase inhibitor that reduces conversion of androgens to estrogens by >99.1% [27] thereby providing a tool to study the role of estrogens during pregnancy, without otherwise interfering in the normal development of pregnancy.
Therefore, the objectives of this study were to suppress estrogen synthesis during late pregnancy in the mare to test the hypothesis that chronic estrogen suppression alters uteroplacental blood flow and fetal development. Specifically, we evaluated the effects of chronic suppression of estrogen synthesis starting at 240 days of gestation on (1) maternal endocrine profiles; (2) uterine artery hemodynamics as determined by Doppler ultrasound indices (resistance and pulsatility indices as well as uterine artery diameter); and (3) gestational length, neonatal weights, and neonatal viability.
Materials and methods

Animals
All experimental procedures were approved by the Institutional Animal Care and Use Committee of the University of Kentucky (Protocol #: 2013-1067). Twelve pregnant, multiparous mares of mixed breeds with a mean age of 14.5 years (range: 6 to 19) and mean weight of 519.4 kg (range: 425 to 594) were kept in paddocks and supplemented with hay, grain, and water ad libitum along with trace minerals. At 240 days of gestation, mares were randomly assigned to control (n = 6) or treatment (n = 6) groups. Treated mares received 500 mg of letrozole (Aurum Pharmatech LLC, Howell, NJ 07731) orally every 4 days until parturition. Dose and frequency of administration were determined based on a previous study in stallions [28] and a pilot study in pregnant mares (Supplement File S1).
Endocrine evaluation
For the evaluation of endocrine changes, blood samples were collected by jugular venipuncture, starting 1 week prior to the beginning of treatment and then on the day of treatment from day 240 to day 315. From day 315, samples were collected daily until parturition. Serum samples were analyzed using enzyme immunoassays (ELISA; enzyme-linked immunosorbent assay). Estradiol-17β (E2) concentrations were determined with a commercial chemiluminescence immunoassay (Immulite estradiol kit; Siemens Healthcare Inc., Malvern, PA, USA) with a range from 20 to 2000 pg/mL and a 20 pg/mL limit of detection. Cross-reactivity reported by the manufacturer as follows: equilin nondetectable (ND), 17α-estradiol 0.032%, estradiol glucuronide ND, estriol 0.535%, estrone 2.09%, estrone sulfate ND, aldosterone ND, androstenedione ND, androsterone ND, cortisol ND, costisone ND, DHEA ND, DHEA-S ND, prednisone ND, progesterone ND, testosterone ND. For progestin determination (P), a previously validated competitive ELISA [29] was used with a range of 0.02-20 ng/mL. The limit of sensitivity of the progestin assay was 0.015 ng/mL. Intra-and inter-assay coefficients of variation (CV) for the progestin immunoassay were 7.5%, and 13.1%, respectively. During the second half of equine gestation, progesterone is virtually undetectable in circulation [30, 31] ; however, a number of other progestins are found in high concentration in circulation and can be measured with progesterone assays due to crossreactivity of the antibody. In this experiment, we use a progesterone assay to evaluate changes in circulating progestins. Serum estrone sulfate (E1S) concentrations were determined with a competitive ELISA [32] . The standard curve ranged from 0.05 to 20 ng/mL, with a limit of detection of 0.049 ng/mL. Intra-assay and inter-assay CVs were 10.2% and 16.6%, respectively. Cross-reactivities of the antibody have been previously reported as follows: estrone glucuronide 70%, estrone 269%, estradiol 9.8%, estradiol glucuronide 4.0%, estradiol sulfate 4.8%. All other cross-reactivities including equilin and equilenin were <0.1% [32] . For testosterone (T), a competitive ELISA was validated in our laboratory using a rabbit polyclonal anti-testosterone antibody (R156/7, Clinical Endocrinology Laboratory, UC Davis), testosterone:horseradish peroxidase (T:HRP, UC Davis), and testosterone for standards (Steraloids Inc., Newport, RI, USA). The standard curve ranged from 0.02 to 10 ng/mL with a limit of detection of 0.02 ng/mL. Intra-and inter-assay CVs were 11.9% and 18.1%, respectively. Previously, cross-reactivity was reported as 29% with 5 α-dihydrotestosterone; 0.5% with androstenedione; and <0.1 for androsterone, estradiol, estrone, estrone sulfate, progesterone and cortisol [33] . The assay was validated against two other commercial assays: a radio immunoassay Coat-a-count Total testosterone RIA (PITKTT-8, Siemens Healthcare Inc., Malvern, PA, USA) and chemiluminescence (Immulite Total testosterone; PILKTW-12, Siemens Healthcare Inc., Malvern, PA, USA). These assays had a correlation with the ELISA of 0.921 and 0.962, respectively. For dehydroepiandrosterone sulfate (DHEA-S), a previously validated competitive ELISA [34] [35] [36] was used with DHEA-S antibody (6N-4; kindly provided by Dr. James Raeside), DHEA-S conjugated with horseradish peroxidase (DHEA-sulfate-3-HRP, CalBioreagents, San Mateo, CA, USA), and DHEA-S for standards (Steraloids Inc., Newport, RI, USA). The standard curve ranged from 0.05 to 20 ng/ml, with a limit of detection of 0.315 ng/mL and an intra-assay CV of 6.5% and inter-assay of 10.3%. Previously, cross-reactivities were reported as DHEA 38.2%, androstenedione 6.6%, epiandrosterone 8.8%, androsterone 3.2%, testosterone, and estrone <0.1% [36] . Maternal serum concentrations of prostaglandin F2α (PGF2α) were determined by measuring concentrations of the prostaglandin metabolite (PGFM) using a commercial kit (PGFM-13,14-dihydro-15-keto-PGF2a, 516671, Cayman Chemical, Ann Arbor, MI, USA) on a monthly basis (8.5, 9.5, and 10.5 months). The limit of detection was 13 pg/mL with a range of 7.8-1000 pg/mL for the standard curve. This assay was previously validated for the horse [37] . Changes in endocrine parameters during the immediate peripartum period (from 4 days preceding parturition) were assessed relative to the day of foaling and compared between treatment groups in a separate statistical analysis.
Ultrasound evaluation of pregnancy
For all ultrasound evaluations, the operator was blinded to the experimental groups. Fetal and placental biometrics and uterine artery blood flow indices were determined by B-mode ultrasonography and pulse-wave power Doppler ultrasonography, respectively, using a 5-10 mHz linear transducer (SonoScape S8, SonoScape Co Ltd., Sonomed; Rome, Italy). Ultrasound measurements were performed transrectally every second week starting at 240 days until parturition. For evaluation of fetal growth, an estimate of fetal size was determined based on the diameter of the fetal eye orbit. Briefly, an ultrasound image of a cross section of the fetal head was obtained until the eye orbit with the lens was visualized, and the height and width of the orbit were averaged [38] . The combined thickness of the uterus and placenta (CTUP) was measured to assess changes in placental development [39] [40] [41] . The ultrasound transducer was positioned at the cervical-placental junction, and the thickness of the uterus and placenta ventrally was measured thrice and averaged [40] .
For evaluation of uterine artery hemodynamics, both left and right uterine arteries were evaluated by transrectal ultrasonography. In sum, the caudal aspect of the abdominal aorta was identified, and the external iliac artery was traced laterally until the deep circumflex artery and uterine arteries diverged. Determinations of uterine artery diameters and Doppler indices were made at this point [42] . Doppler indices, pulsatility index (PI), and resistance index (RI) were determined with the pulse wave power Doppler ultrasound gate set around the uterine artery and an angle of correction between 30
• and 60
• . Three consecutive waveform sequences were recorded, and spectral analysis was used to obtain PI and RI (SonoScape S8; SonoScape Co Ltd., Sonomed, Rome, Italy).
Parturition and neonatal assessment
At parturition, a complete physical examination of foals and mares and macroscopic evaluation of the placentas were performed. Foals were kept under observation for a week to assess viability and normal development, which was evaluated based on length of gestation, as well as weights of neonates, placentas, mares, and ratios of foal to dam and placenta to foal weights.
Statistical analysis
Data were tested for homogeneity of variance by the Levene test, and log transformations were performed on data that were determined to have heterogeneous variances prior to analysis. Model assumptions were evaluated by examining normal quantile plots of residuals. Data from endocrine evaluations, fetal growth, CTUP, and hemodynamic parameters were analyzed using a mixed-model ANOVA with fixed effects of gestational age, treatment and treatment × gestational age and mare as a random effect. The Tukey honest significant difference (Tukey HSD) procedure was used for post hoc analyses. Endocrine data were evaluated from 8 months until 10.5 months (prior to the first parturition) and, in a separate analysis, the last 4 days of gestation and the day of foaling. Weights of the foal, the dam, and the placenta as well as gestational length were analyzed using the Welch's test. One control mare suffered a dystocia during parturition which resulted in a dead neonate. Data on this foal were not included in the analyses. All data were analyzed using JMP 11 software (SAS Institute Inc., Cary, NC). Data are presented as means ± SEM, and statistical significance was set at P < 0.05.
Results
Endocrine analyses
Estradiol and estrone sulfate concentrations were significantly suppressed for the duration of the treatment (Figure 1 ). There were interactions between treatment by gestational age for both estrogens (P < 0.0001) and an effect of gestational age (P < 0.0001). In the first posttreatment samples, circulating estradiol concentration decreased from 422.0 ± 66.6 in controls to 48.1 ± 20.9 pg/mL in letrozoletreated mares and estrone sulfate decreased from 859.0 ± 83.1 to 77.8 ± 14.6 ng/mL, net declines of 89% and 91% respectively with letrozole treatment. Conversely, circulating testosterone and DHEA-S concentrations were increased for the duration of the treatment (Figure 2 ). There were interactions between treatment by gestational age for testosterone (P < 0.0001) and DHEA-S (P < 0.0005) and an effect of gestational age for these androgens (P < 0.0001). Progestins did not show an interaction between treatment and gestational age (P = 0.46) but did increase over time (P < 0.0001) Figure 1 . Peripheral serum estradiol-17β and estrone sulfate in pregnant mares treated with 500 mg of letrozole every 4 days (n = 6; open circles) and control mares (n = 6; black circles). Letrozole treatment was initiated at 8 months of gestation (arrow) and continued until parturition. Values represent mean ± SEM for weekly samples. For both estrogens, there was an interaction of treatment by gestational age (P < 0.0001) as well as an effect of gestational age (P < 0.0001).
Figure 2.
Peripheral serum testosterone and DHEA-S in pregnant mares treated with 500 mg of letrozole every 4 days (n = 6; open circles) and control mares (n = 6; black circles) starting at 8 months of gestation (arrow). Values represent mean ± SEM for weekly samples. Both testosterone and DHEA-S had an interaction of treatment by gestational age (P < 0.0001 and P < 0.0005 respectively) and an effect of gestational age (P < 0.0001).
( Figure 3) . Concentrations of PGFM were significantly lower in the letrozole-treated group (P < 0.05) (Figure 3 ).
In the 4 days prepartum, peripheral estrogen concentrations declined in both groups ( Figure 4) ; however, estrogens were already significantly lower in treated than in control mares. Peripheral testosterone, DHEA-S, and progestins declined in the 4 days prepartum; however, there were no differences between treated and control mares (data not shown). Differences in hormone concentrations were also measured in serum from neonatal foals ( Table 1) . Both estrogens were significantly higher in controls, but testosterone and progestins were not significantly different in foals from treated versus control mares.
Ultrasonographic determination of fetal growth, placental thickness, and uterine artery hemodynamics Doppler ultrasonography did not reveal any interaction of treatment with gestational age ( Figure 5) ; however, both PI and RI decreased over time in control and letrozole-treated mares (P = 0.015 and P < 0.0001, respectively) indicating an increase in uterine blood flow with increasing gestational age. Additionally, the diameter of the uterine artery increased (P < 0.0001) as gestational age progressed in both groups independent of letrozole treatment.
During the treatment period, CTUP and diameter of the fetal eye orbit were not affected by letrozole treatment (Figure 6 ), but both increased with gestational age (P < 0.0001).
Neonatal parameters
Neonatal foals from treated mares weighed less (P < 0.05) than foals from control mares ( Table 2 ). In addition to the lower birth weights, the percentage of foal-to-dam weight was lower (P < 0.05) in the letrozole-treated group. There were no treatment effects on the length of gestation, placental weight, ratio of placenta-to-foal weight, or neonatal viability. One control mare had a dystocia due to fetal malposture resulting in death of the foal. All other foals from both groups had no apparent problems during delivery, standing, or suckling.
Discussion
The results of this study supported our hypothesis that chronic suppression of maternal estrogens during late pregnancy in the mare impairs fetal growth but do not support the idea that this impaired fetal growth was associated with altered uteroplacental blood flow. As is well known [16] and confirmed in this study, circulating Peripheral serum progestins and PGFM in pregnant mares treated with 500 mg of letrozole every 4 days (n = 6; open circles) and control mares (n = 6; black circles) starting at 8 months of gestation (arrow). Values represent mean ± SEM weekly samples for progestins and monthly samples for PGFM (each group n = 6). There was no interaction of gestational age by treatment for progestins (P = 0.46); however, there was a significant effect of gestational age (P < 0.0001). For PGFM, there was an interaction of gestational age by treatment (P < 0.05).
Figure 4.
Peripheral serum estradiol and estrone sulfate in pregnant mares for controls and mares treated with 500 mg of letrozole in the last 5 days of gestation (0 being the first day postpartum). Values represent mean ± SEM daily samples analyzed (each group n = 6). Estrone sulfate showed large differences between treated and control groups with significant effect of time (P < 0.0001), group (P < 0.0001), and interaction of time by group (P < 0.0001). For estradiol, there were significant effects of time (P < 0.0001), and interaction of time by treatment (P < 0.001). estrogens are elevated throughout equine pregnancy. These high maternal concentrations of estrogens during the second half of gestation are thought to be important for normal fetal development, possibly via their action on uterine and placental blood flow [17, 18] . Our results indicate that a large and sustained reduction in peripheral estrogens was not associated with changes in normal uterine artery hemodynamics during the second half of equine gestation; Doppler indices and uterine artery diameters were similar to normal gestational parameters [43] [44] [45] . With advancing gestational age, uterine arterial diameter increased while PI and RI decreased in both treated and control mares. These changes are directly proportional to the increase in uterine blood flow associated with the increased demands of fetal growth during gestation [44, 46] . Based on these findings, it appears that the elevated concentrations of estrogens present in the last trimester of equine pregnancy are not required to maintain low-resistance blood flow in the uterine artery. It is important to recognize that even though estrogens are elevated during late gestation in the mare, levels are steadily decreasing in normal pregnancies from around 7 months of gestation until parturition [5, 12, 17, 18] . The decreasing levels of estrogens during late gestation are unique to the horse and different from most known mammalian species [6, [8] [9] [10] .
In nonpregnant animals, estrogens play an important role in the vasodilatory response of the uterine vascular bed [6, 20, 21, 47] . These studies indicate that several estrogens have a potent vasodilatory effect on uterine arteries, and thus an increase in uterine blood flow in nonpregnant animals. The results from our experiments Figure 5 . Comparison of the uterine artery hemodynamics assessed by color Doppler ultrasonography. Uterine artery diameters, PI, and RI were evaluated on a biweekly basis. Values represent the mean ± SEM for the letrozole-treated mares (n = 6) and control mares (n = 6). Treatment was initiated at 8 months. Uterine artery diameters increased over time (P < 0.0001) but there was no interaction of gestational age by treatment. Similar results were obtained for the Doppler indices. There was no significant interaction between gestational age and treatment; PI (P = 0.48), RI (P = 0.55), but both indices decreased over time with a significant decrease in RI (P < 0.0001) and PI (P = 0.015). Figure 6 . Fetal eye orbit and CTUP as determined by ultrasonography. Control mares and letrazole-treated mares were evaluated on a biweekly basis (each group n = 6). Both parameters had a significant effect of gestational age (P < 0.0001) but no interaction of gestational age by treatment. Data are mean ± SEM.
suggest that the increased uterine blood flow during later stages of gestation was, to a considerable extent, independent of the circulating concentrations of estrogens. However, estrogen synthesis was not completely ablated in letrozole-treated mares, and circulating estrogen concentrations remained elevated when compared to mares during estrus or early pregnancy. Therefore, it is possible that the concentrations of estrogen present in late gestation in treated mares were sufficient to maintain low impedance uterine blood flow.
Studies in several species have shown that estrogens appear to stimulate placental angiogenesis during early pregnancy with little or no effect on angiogenesis during late gestation [48] [49] [50] [51] [52] . In sheep, the majority of the increase in uterine blood flow during pregnancy, 7.5 ± 0.4 7.9 ± 0.6
Asterisk indicates significant difference (P < 0.05). All values, except number and sex ratios of live foals, are expressed are mean ± SEM.
unlike the follicular phase [53, 54] , is due to angiogenic and vascular growth processes which occur during early gestation [49] [50] [51] . This vascular remodeling appears to occur earlier in gestation than the period encompassed by the current study in mares. In baboons, estrogens appear to stimulate remodeling of the uterine arteries during the first half of gestation [48, 52] . This remodeling is responsible for changing high resistance, low capacity arteries into low resistance, high capacity arteries [55] . Therefore, despite the suppression of maternal estrogen concentrations by approximately 95% in letrozole-treated baboons, uterine artery hemodynamics remained similar to controls as determined by PI and RI during the second half of gestation. Aberdeen et al. [55] suggest that the vasoregulatory mechanisms are diminished during the second half of gestation which explains the increased uterine blood flow during later stages of gestation regardless of estrogen deprivation. Therefore, estrogen-mediated vasodilation might be a gestational age-specific event present during earlier stages of gestation, as suggested by the lack of changes in uterine hemodynamics after the inhibition of estrogen production in late gestation reported in baboons [55] and as noted in pregnant mares in the current study. However, Magness et al. showed that high doses of the estrogen receptor antagonist ICI 182 780 caused a reduction of approximately 37% in uterine artery blood flow during late gestation in sheep [47] , indicating that uterine blood flow regulation is partially mediated by estrogen receptor-dependent mechanisms during late gestation. This decrease might be associated with species-specific differences in the regulatory mechanisms of vasodilation during pregnancy or, alternatively, could indicate that directly blocking the estrogen receptor was more effective than the >90% reduction in estrogen synthesis induced by letrozole treatment in horses or baboons. Furthermore, despite the high doses of estrogen receptor antagonist used in sheep, uterine blood flow was only moderately affected, which is compatible with the remodeling of the uterine arteries during early gestation and the diminished vasoregulatory mechanisms during late gestation. Recent studies by our laboratory suggest that estrogen suppression during earlier stages of gestation had an effect on uteroplacental angiogenic factors (unpublished data; [56] ) which also supports the idea of critical vascular remodeling during early stages of pregnancy in mares.
In the current study, we evaluated only the classical estrogens, estrone and estradiol, but did not evaluate the ring B-unsaturated equilin or equilenin. These equine-specific estrogens are present in high concentrations during pregnancy, and their formation also depends on aromatase [57] [58] [59] . Therefore, letrozole might be expected to also suppress the synthesis of the ring-B unsaturated estrogens during pregnancy and their estrogenic effects. The decrease in synthesis of estrogens was also associated with a large increase in testosterone and DHEA-S potentially due to the block in aromatization through inhibition of aromatase. The increase in testosterone and DHEA-S was similar to the results obtained by inhibiting aromatase in the pregnant baboon [55] . However, the increase in testosterone and DHEA-S did not account for the large decrease in estrone sulfate; this discrepancy could be due to shunting of metabolites into other androgens which were not measured or possibly to the relatively longer half-life of the sulfoconjugates. Previous research in pigs showed that administration of letrozole also suppressed circulating levels of estrogens and estrogen conjugates without an increase in circulating testosterone [60, 61] , which suggests alternative metabolic routes. Furthermore, an earlier report in pregnant mares did not find a strong association between DHEA and estrone concentrations [62] , which could also account for differences found in this study.
The fact that the CTUP of the letrozole-treated mares was not altered is interesting because the evaluation of the thickness of the uterus and placenta has been used as an indicator of placental pathology [39, 40] , and CTUP normally increases from approximately 4 mm at 8 months to 10 mm in the last month of gestation [40] . This increase in the thickness of the placenta during the last few months of gestation [40] is thought to be associated with elevated blood flow to the uterus during the last trimester of equine gestation to meet the nutritional demands of the fetus during the later stages of development [44] . In addition, increases in the CTUP above normal limits have been associated with placental pathology [41] , which is also associated with low circulating estrogen concentration. However, the CTUP of the letrozole group remained similar to that of controls, which suggests that estrogens were not associated with either the physiological or the pathological increase in placental thickness during the last trimester of equine pregnancy.
In the current study, the suppression of estrogens reduced fetal growth in late gestation through an unknown mechanism which was not associated with alteration in uterine arterial blood flow. Foal weight at birth was significantly lower in foals from letrozole-treated mares than those from controls, with birth weights decreased by 14% in foals from letrozole-treated mares. Three alternative explanations of the difference in neonatal weights without differences in uterine blood flow can be offered. First, letrozole treatment could be responsible for the differences in neonatal weights independent of estrogen suppression. However, previous research in baboons indicated that letrozole treatment alone had no independent effects when compared to controls or letrozole-treated animals with estradiol replacement therapy [55] . Estrogen replacement therapy was considered for the current study in an additional letrozole-treated group. However, it has been shown that chronic estrogen replacement therapy would be impractical due to the high concentration of circulating estrogens present during late gestation in the horse [63] . Second, it has been shown that estrogen administration increased expression of vascular endothelial growth factor (VEGF) in the uterus [64] and placenta [65] of baboons. Therefore, the effects on fetal growth may have been mediated by alterations in placental vascularization without changes in uterine artery hemodynamics secondary to estrogen suppression. Third, it is also possible that aromatase inhibition and estrogen suppression influenced fetal maturation independent of uterine blood flow. In baboons, estrogens are important for other aspects of fetal development independent of uterine blood flow, such as activation of fetal pituitary adrenocortical axis [66, 67] , fetal adrenocortical maturation [68] , and fetal ovarian development [69] . Therefore, the estrogen deprivation might be responsible for the differences in fetal weight but through another mechanism independent of blood flow or placental vascularization.
Fetal gender is also known to potentially influence birth weights in the horse. However, differences in the distribution of fetal gender between treatment groups in the current study were not associated with differences in neonatal weights between groups. It is noteworthy that although letrozole-treated foals were smaller, fetal eye orbit diameter did not show any differences between treatments. This disparity could be due to lack of sensitivity in the ultrasonographic determinations or because differences in foal weights were not related to the development of skeletal system but to the overall weight of the foals including growth in soft tissues.
Although fetal growth was altered in letrozole-treated mares, there were no significant changes in gestational length or neonatal viability with letrozole treatment, as foals were born unassisted and appeared normal at birth. These results confirm that high maternal concentrations of estrogens are not necessary for the maintenance of pregnancy during the last few months of gestation as already described in horses and baboons [17, 18, 55] . Therefore, low estrogen concentrations associated with compromised pregnancies in horses [24, 25] would seem to be the result of other concurrent pathological processes rather than the cause of the abortions. The normal unassisted delivery of viable foals in this study differs from the reports of Pashen and Allen where gonadectomy of fetuses during pregnancy similarly resulted in low maternal estrogen concentrations during late gestation. In the study by Pashen and Allen, three of four gonadectomized foals needed assistance during delivery and showed marked prematurity/dysmaturity with a high neonatal mortality [17, 18] . The difference in maturity and viability of the foals between these studies and this study may be related to the gonadectomy. The surgical procedure for fetal gonadectomy may have also contributed to abnormal fetal development; however, sham-operated pregnancies that made it to term delivered a live and mature foal. Therefore, it appears unlikely that the surgical procedure caused the dysmaturity/prematurity of gonadectomized foals, and the reasons for the disparity between fetal outcomes in these studies are unclear.
In addition to altered fetal growth, suppression of estrogen during late pregnancy in the mare was associated with a decrease in circulating PGF2α metabolites. The role of prostaglandins, specifically PGF2α during equine gestation and parturition, was also evaluated in pregnancies with gonadectomized fetuses [17, 18, 70] . These studies showed that prostaglandins during equine gestation are of fetal origin and that PGF2α is necessary during parturition. PGFM was drastically reduced in mares carrying gonadectomized fetuses, and deliveries were compromised. In our study, estrogen suppression resulted in a decrease in circulating PGFM, which suggests that estrogens partially regulate prostaglandin production during pregnancy, since PGFM concentrations were lower but still increased during the last trimester of equine gestation in letrozole-treated mares. In contrast to the reports of Pashen and Allen, the reduced circulating PGFM did not interfere with parturition in mares with chronically suppressed estrogen concentrations in late pregnancy.
In conclusion, chronic suppression of maternal estrogens with letrozole during the last trimester of equine pregnancy reduced neonatal weights and ratios of foal to mare weight by 14% and 17%, respectively, despite the lack of effect a detectable effect on uterine artery hemodynamics, gestational length, parturition, or neonatal viability. The mechanism for this reduction in neonatal weight remains uncertain and requires further investigation. Additionally, experiments during earlier stages of pregnancy might elucidate if estrogens in fact regulate uterine blood flow and vascular remodeling during the first half of equine gestation.
